• Vaccine Name: HIV DNA vaccine pHIS-SHIV-B
• Target Pathogen: Human Immunodeficiency Virus
• Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
• Vaccine Ontology ID: VO_0004348
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Monkey
• Antigen: full-length unmutated SIVmac239 Gag and Pol, HIV-1AD8, Tat, Rev, and Vpu, and the 5′ third of HIV-1AD8 Env (Dale et al., 2004)
• env gene engineering:
  • Type: DNA vaccine construction
  • Description: The DNA vaccine strain, pHIS-SHIV-B, encoded full-length unmutated SIVmac239 Gag and Pol, HIV-1AD8, Tat, Rev, and Vpu, and the 5′ third of HIV-1AD8 Env (Dale et al., 2004).
  • Detailed Gene Information: Click Here.
• Gag protein from SIV-mnd 2 gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• Pol SIV gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• Tat gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• rev from HIV 1 gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• vpu gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid: pHIS64 DNA vaccine plasmid
  • DNA vaccine plasmid name: pHIS64 DNA vaccine plasmid
  • DNA vaccine plasmid VO ID: VO_0000209
• Immunization Route: Intramuscular injection (i.m.)

Macaque Response

• Vaccine Immune Response Type: VO_0000286
• Efficacy: DNA vaccination alone primed for protection almost as effectively as the DNA/fowlpox virus regimen (Dale et al., 2004).
• Host IFNG from Macaca nemestrina response
  • Description: SIV Gag-specific CD8 T cells expressing IFN-γ were dramatically boosted after challenge. Mean Gag-specific CD8 T cells peaked 3 weeks following challenge at 11.7% of all CD8 T cells in these outbred pigtail macaques immunized with the 2DNA/FPV regimen. The other vaccine groups had lower mean postchallenge CD8 T-cell responses, with peak responses at week 2 following challenge numbering 3.8% in the 3DNA group, 1.1% responses in the 1DNA/FPV group, and 2.0% in the 2DNA/FPV-IFN-γ-immunized animals (Dale et al., 2004).
  • Detailed Gene Information: Click Here.